You are here: Industry Insights > DURECT

News List

First Patient Dosed in DUR-928 Study for Severe Alcohol-Associated Hepatitis americanpharmaceuticalreview
January 29, 2021
DURECT has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.
DURECT Announces Positive Topline Data from NASH Study americanpharmaceuticalreview
June 02, 2020
DURECT Corporation announced positive topline results from its Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients.
DURECT Announces Outcome of POSIMIR FDA Advisory Committee Meeting americanpharmaceuticalreview
January 19, 2020
DURECT announced the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution).
DURECT Announces Top-Line Results from Psoriasis Clinical Trial americanpharmaceuticalreview
January 03, 2020
DURECT announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study ...
DURECT Receives POSIMIR® CRL americanpharmaceuticalreview
July 18, 2019
DURECT announced the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it previously received from ...